Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Emapalumab for Prevention of Liver Failure in Pediatric Indeterminate Severe Hepatitis Associated With T-Cell Activation: Severe Hepatitis Intervention With Emapalumab for Liver Disease

NCT07744919 is registered in ClinicalTrials.gov with Children's Healthcare of Atlanta as lead sponsor.

NCT NCT07744919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07744919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Emapalumab for Prevention of Liver Failure in Pediatric Indeterminate Severe Hepatitis Associated With T-Cell Activation: Severe Hepatitis Intervention With Emapalumab for Liver Disease
Lead sponsor
Children's Healthcare of Atlanta
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 30, 2032
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis